24 results
8-K
STRO
Sutro Biopharma Inc
8 Jan 24
Results of Operations and Financial Condition
7:31am
.
Updated luvelta Data:
An aggregated analysis of nearly 100 women with ovarian cancer from Company’s Phase 1 program led to the following observations
8-K
EX-99.1
STRO
Sutro Biopharma Inc
8 Jan 24
Results of Operations and Financial Condition
7:31am
expressing FolR⍺ (≥75% TPS with PS 2+, 3+) Luvelta Demonstrated the Ability to Treat 8 out of 10 Women with Ovarian Cancer Due to FolRα expression ≥25
8-K
EX-99.1
0nmvh8d68v
9 Aug 21
Business Highlights and Anticipated Second Half 2021 Milestones
7:01am
8-K
EX-99.1
l4cvl
7 May 21
Business Highlights and 2021 Anticipated Milestones
7:00am
8-K
EX-99.1
pqu6c kwc093hp58
18 Mar 21
Sutro Biopharma Reports Full Year 2020 Financial Results
7:00am
8-K
EX-99.1
sms67oz3l t7
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.2
3in p3pkeu
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.2
efkomnr97
9 Sep 20
Other Events
5:23pm
8-K
EX-99.1
uvlnpb zp1
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.1
wsq db41ehtdqbxz
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
8-K
EX-99.1
rjtl9qnic7cr q7u2vs1
14 Aug 19
Sutro Biopharma Reports Second Quarter 2019 Financial Results
12:00am
8-K
EX-99.1
hnvd57ayoi
15 May 19
Sutro Biopharma Reports First Quarter 2019 Financial Results
7:00am
8-K
EX-99.1
b2gr03 1i0o
1 Apr 19
Sutro Biopharma Reports Full Year 2018 Financial Results
10:22am